Freedom of Information

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

• Belantamab Mafodotin [Blenrep]
• Bortezomib [Velcade] monotherapy or with dexamethasone
• Bortezomib, thalidomide and dexamethasone [VTD]
• Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
• Carfilzomib [Kyprolis] and dexamethasone
• Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
• Daratumumab [Darzalex] monotherapy
• Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
• Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
• Elranatamab
• Idecabtagene vicleucel [Abecma]
• Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
• Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
• Lenalidomide [Revlmid] monotherapy
• Lenalidomide [Revlimid] and dexamethasone
• Pomalidomide [Imnovid] and dexamethasone
• Selinexor and dexamethasone
• Talquetamab
• Teclistamab [Tecvayli]
• Any other systemic anti-cancer therapy